Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics, Inc. (Nasdaq: CODX) has announced regulatory authorization for its Logix Smart™ ABC test for Influenza A/B and the Logix Smart™ SARS-CoV-2 multiplex test, allowing sales in CE-marking markets. These tests enable simultaneous detection of influenza and COVID-19, addressing the need for accurate diagnostics amid overlapping symptoms. The company's CoPrimer™ technology enhances test specificity, reducing false positives. The CE markings facilitate immediate export and sales in the European Community and other global markets.
Co-Diagnostics, Inc. (CODX) reported strong Q3 2020 results with revenues of $21.8 million and a net income of $15.7 million, equating to $0.53 per diluted share. YTD net income reached $29.7 million. The company received CE markings for two key products: the Logix Smart ABC test and the SARS-CoV-2 multiplex test. A substantial increase in stockholders' equity to $52.7 million from $1.7 million at the year's start was noted. CoSara Diagnostics reported $3.0 million in Q3 revenue, a threefold increase from Q2.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that their CoPrimer™ platform can detect SARS-CoV-2 directly from saliva samples without RNA extraction. The company’s whitepaper highlights the technology's efficiency in providing rapid and cost-effective COVID-19 testing. CEO Dwight Egan emphasized the market potential for extraction-free tests, indicating plans to integrate these into their offerings. The recent collaboration with Clinical Reference Laboratory (CRL) will enhance consumer access to their saliva-based tests, further positioning CODX as a leader in molecular diagnostics.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced it will release its third quarter 2020 earnings on November 16, 2020, after market close. An earnings call will be hosted at 4:30 PM EDT, featuring prepared remarks from CEO Dwight Egan and a Q&A session for analysts. The call will be recorded and later accessible on the company's website. Co-Diagnostics focuses on developing innovative molecular diagnostics technology and utilizes its proprietary methods to create tests for various industries, including infectious diseases.
Co-Diagnostics, Inc. (Nasdaq: CODX) is set to amend its Q2 2020 Form 10-Q due to an incorrectly recorded expense. This amendment will reflect an increase in basic and diluted net income per share to $0.51, up from a previously reported $0.08. The amended report is expected to be filed before the Q3 2020 Quarterly Report. The company focuses on the development of molecular diagnostic tests utilizing its proprietary technology.
Co-Diagnostics (Nasdaq: CODX) announced that Access Genetics' OralDNA Labs received an amended Emergency Use Authorization (EUA) for a COVID-19 RT-PCR test, utilizing Co-Diagnostics' Logix Smart™ COVID-19 kit. This test allows for a saline oral rinse collection, which could enhance testing comfort and accessibility. CEO Dwight Egan noted that this represents the first FDA authorization for a test using oral rinse technology, underscoring the adaptability of the company's CoPrimer™ platform. The announcement highlights the potential for improved community testing.
Co-Diagnostics (NASDAQ: CODX) announced that its Logix Smart™ ABC Test for Influenza A, Influenza B, and COVID-19 is set to launch for US CLIA laboratory customers in early October 2020. The test utilizes the patented CoPrimer™ technology designed to minimize false positives in PCR tests, addressing the critical need for accurate viral detection amidst the ongoing pandemic. The initial release will be for laboratory-developed tests while the company seeks FDA Emergency Use Authorization and CE marking registration.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced details regarding CEO Dwight Egan's upcoming presentation at H.C. Wainwright's 22nd Annual Global Investment Conference on September 14, 2020, at 10:00 ET. The presentation will showcase the company's growth, profitability, and future goals. Investors and interested parties can register to view the live presentation and access an archive for 90 days thereafter. Co-Diagnostics specializes in molecular diagnostics, utilizing proprietary technology to develop tests for nucleic acid detection and analysis, which extends beyond infectious diseases.
Co-Diagnostics, Inc. (Nasdaq: CODX) reports significant growth and demand for its Logix Smart™ COVID-19 test amid the ongoing pandemic. The RT-PCR tests are recognized as the 'gold standard' for detecting SARS-CoV-2, with rising global interest in PCR-based diagnostics. The company is enhancing its offerings by introducing a respiratory virus panel to test for influenza A, influenza B, and COVID-19. Co-Diagnostics continues collaborations with government and private sectors, expanding its reach in high-throughput laboratories across the U.S. and globally.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that CEO Dwight Egan will discuss the company's growth and profitability at H.C. Wainwright's 22nd Annual Global Investment Conference on September 14, 2020. The company has experienced a remarkable 1,503% increase in Q2 2020 revenue, totaling over $24 million, and transitioned from a loss to earnings of over $12 million. Egan will recap financial and regulatory achievements, emphasizing Co-Diagnostics' leadership in molecular diagnostics amidst the COVID-19 pandemic and its expansive distributor network.